Leonardo Pipek
Hospital ResidentCards
About
Research
Publications
2026
Efficacy and safety of adjuvant tirofiban versus intravenous thrombolysis alone in acute ischemic stroke: an updated meta-analysis of randomized controlled trials
Leite M, Ribeiro Gonçalves O, de Almeida Monteiro G, Marinheiro G, Mutarelli A, Pereira da Silva A, Andrade Fernandes J, Pensenstadler K, Singh J, Lee W, Pipek L, Mota Telles J. Efficacy and safety of adjuvant tirofiban versus intravenous thrombolysis alone in acute ischemic stroke: an updated meta-analysis of randomized controlled trials. Journal Of Thrombosis And Thrombolysis 2026, 1-12. PMID: 42315720, DOI: 10.1007/s11239-026-03335-y.Peer-Reviewed Original ResearchRandomized Controlled TrialsSymptomatic intracranial hemorrhageModerate-to-severe disabilityAcute ischemic strokeIntracranial hemorrhageCochrane Central RegisterIntravenous thrombolysisFunctional statusRisk ratioControlled TrialsConfidence intervalsMean differenceMeta-analysisIVT-treated AIS patientsMeta-analysis of randomized controlled trialsCochrane Central Register of Controlled TrialsIschemic strokeCentral Register of Controlled TrialsRegister of Controlled TrialsRandom-effects modelIVT-treated patientsClinical guidelinesMortality riskAdjuvant therapyNeurological improvementResponse to: “INTERACT3 in Intensive Blood Pressure Meta‑Analysis: A Methodological Reappraisal”
Reginato P, Neves H, Pipek L. Response to: “INTERACT3 in Intensive Blood Pressure Meta‑Analysis: A Methodological Reappraisal”. Neurocritical Care 2026, 1-3. PMID: 42303960, DOI: 10.1007/s12028-026-02557-5.Peer-Reviewed Original ResearchMedical Cannabis in the Treatment of Non-motor and Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta-analysis (P6-17.013)
Pascual G, Pipek L, Reginato P, Parmera J. Medical Cannabis in the Treatment of Non-motor and Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta-analysis (P6-17.013). Neurology 2026, 106 DOI: 10.1212/wnl.0000000000216378.Peer-Reviewed Original ResearchThe authors reply:
Pipek L, Pascual G, Nascimento R, Silva G, Castro L. The authors reply:. Critical Care Medicine 2026, 54: 681-682. PMID: 41773931, DOI: 10.1097/ccm.0000000000007035.Commentaries, Editorials and Letters
2025
Response to “When Precision Meets Bias: Questioning the Validity of Pooled Estimates in Intensive Blood Pressure Lowering for Intracerebral Hemorrhage Meta-analyses”
Reginato P, Mantovani G, da Silva Castro V, Pascual G, Saldanha L, Neves H, Pipek L. Response to “When Precision Meets Bias: Questioning the Validity of Pooled Estimates in Intensive Blood Pressure Lowering for Intracerebral Hemorrhage Meta-analyses”. Neurocritical Care 2025, 44: 738-740. PMID: 41398514, DOI: 10.1007/s12028-025-02419-6.Commentaries, Editorials and LettersAssociation between vitamin D deficiency and subarachnoid hemorrhage: a systematic review
da Silva V, Manicardi R, Brito J, de Sena Barbosa M, Pipek L, Telles J, Welling L, Baldoncini M, Campero A, Chavda V, De Oliveira Dourado J, Chaurasia B, Rabelo N. Association between vitamin D deficiency and subarachnoid hemorrhage: a systematic review. Annals Of Medicine And Surgery 2025, 87: 6443-6450. PMID: 41181431, PMCID: PMC12578030, DOI: 10.1097/ms9.0000000000002798.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsVitamin D deficiencyVitamin D levelsD deficiencySubarachnoid hemorrhageD levelsOccurrence of subarachnoid hemorrhageSerum levelsVitamin DSystematic reviewSerum level of 25(OH)DSerum vitamin D levelsRisk factorsLow vitamin D levelsLevels of 25(OH)DSubarachnoid hemorrhage occurrenceVitamin D receptorNon-traumatic casesPreventable risk factorsVitamin D evaluationSystematic review of studiesVitamin D functionRegulating blood pressurePatient prognosisD receptorBlood pressureNutritional Emergencies
Kamel A, Shah P, Pipek L, Shah A, Kandiah P. Nutritional Emergencies. Current Surgery Reports 2025, 13: 30. DOI: 10.1007/s40137-025-00465-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcetylcholinesterase Inhibitors for Delirium Prevention: A Systematic Review and Meta-Analysis
Pipek L, Pascual G, Nascimento R, Silva G, Castro L. Acetylcholinesterase Inhibitors for Delirium Prevention: A Systematic Review and Meta-Analysis. Critical Care Medicine 2025, 53: e2054-e2061. PMID: 40758382, DOI: 10.1097/ccm.0000000000006786.Peer-Reviewed Original ResearchConceptsLength of stayHospital length of stayTreatment of deliriumHospitalized patientsDelirium durationSubgroup analysisHospital lengthAssociated with significant morbidityDelirium occurrenceOccurrence of deliriumRisk of Bias 2Random-effects modelPlacebo groupSeverity of deliriumAcetylcholinesterase inhibitorsFrequent complicationNo significant differenceSignificant morbidityAdverse eventsElective surgeryPatient populationProphylaxisSecondary outcomesWeb of SciencePatientsIntensive Blood Pressure Lowering for Intracerebral Hemorrhage: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials
Reginato P, Mantovani G, Furtado da Silva Castro V, Salema Pascual G, Felício Saldanha L, Ferreira Neves H, Pipek L. Intensive Blood Pressure Lowering for Intracerebral Hemorrhage: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials. Neurocritical Care 2025, 43: 864-875. PMID: 40739079, DOI: 10.1007/s12028-025-02325-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRandomized Controlled TrialsIntensive BP loweringHematoma enlargementPoor functional outcomeFunctional outcomesBlood pressureBP loweringSubgroup analysisLibrary databasesRisk ratioLow riskIntensive blood pressure loweringMeta-analysis of randomized controlled trialsStandard managementResultsEleven randomized controlled trialsControlled TrialsLow risk of deathAssociated with elevated blood pressureMeta-analysisBlood pressure loweringCochrane Library databasesElevated blood pressureAll-Cause MortalityConfidence intervalsSystematic reviewCould rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs
Silva G, Pipek L, de Oliveira M, Apóstolos-Pereira S, Adoni T, Lino A, Callegaro D, Castro L. Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs. The Lancet Regional Health - Americas 2025, 49: 101171. PMID: 40688562, PMCID: PMC12271893, DOI: 10.1016/j.lana.2025.101171.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMultiple sclerosisWorld Health Organization's listAssociated with lower overall treatment costsLower overall treatment costsB-cell depleting agentsAssociated with better long-term outcomesHigh-efficacy therapyFirst-line therapyEarly treatment optionLong-term outcomesHealthcare system costsMultiple sclerosis treatmentOverall treatment costsHealth inequalitiesRelapse rateRituximabSafety profileTreatment optionsB cellsCost-saving treatmentOff-labelEarly treatmentRandomized trialsNeurological disabilityPatient organizations